Gossamer Bio, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $37.7M-18.1% | $46.1M+43.5% | $32.1M-71.3% | $112.0M-38.9% | $183.4M |
| Marketable securities | $99.2M-60.1% | $248.4M-6.0% | $264.3M+83.9% | $143.7M+1.3% | $141.8M |
| Receivable from contracts with collaborators | $12.2M+129.1% | $5.3M | $0 | — | — |
| Prepaid expenses and other current assets | $18.5M+84.3% | $10.0M-0.6% | $10.1M+62.8% | $6.2M-4.6% | $6.5M |
| Total current assets | $167.6M-45.9% | $309.9M+1.1% | $306.5M+17.0% | $261.9M-21.1% | $331.8M |
| Property and equipment, net | $64K+540.0% | $10K-99.4% | $1.6M-58.6% | $4.0M-25.2% | $5.3M |
| Operating lease right-of-use assets | $4.1M-19.1% | $5.1M+63.2% | $3.1M-47.0% | $5.9M+7.9% | $5.5M |
| Other assets | $408K+44.2% | $283K-54.2% | $618K-9.1% | $680K-37.0% | $1.1M |
| Total assets | $172.2M-45.4% | $315.3M+1.1% | $311.9M+14.5% | $272.4M-20.7% | $343.7M |
| Accounts payable | $6.0M+157.0% | $2.3M-58.0% | $5.5M+278.8% | $1.5M-55.0% | $3.2M |
| Accrued research and development expenses | $21.7M+107.2% | $10.5M+34.4% | $7.8M-50.2% | $15.6M-3.6% | $16.2M |
| Current contract liabilities | $20.0M+17.2% | $17.1M | $0 | — | — |
| Accrued expenses and other current liabilities | $15.8M+4.2% | $15.2M-43.1% | $26.7M+29.9% | $20.5M+0.6% | $20.4M |
| Total current liabilities | $63.4M+40.9% | $45.0M-12.8% | $51.6M+4.8% | $49.2M+23.5% | $39.9M |
| Long-term convertible senior notes | $198.5M+0.5% | $197.5M+0.5% | $196.6M+0.5% | $195.7M+30.4% | $150.0M |
| Operating lease liabilities - long-term | $3.5M-21.3% | $4.4M+2954.2% | $144K-95.8% | $3.4M+7.1% | $3.2M |
| Long-term contract liabilities | $29.6M-23.8% | $38.9M | $0 | — | — |
| Total liabilities | $295.0M+3.2% | $285.8M+14.7% | $249.1M-4.3% | $260.4M+17.2% | $222.2M |
| Common stock, $0.0001 par value; 700,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 233,677,057 shares issued and outstanding as of December 31, 2025, and 226,604,138 shares issued and outstanding as of December 31, 2024 | $24K+4.3% | $23K+0.0% | $23K+130.0% | $10K+25.0% | $8K |
| Additional paid-in capital | $1.32B+1.9% | $1.30B+1.7% | $1.28B+22.0% | $1.04B+12.0% | $932.9M |
| Accumulated deficit | -$1.44B-13.4% | -$1.27B-4.7% | -$1.21B-17.4% | -$1.03B-27.2% | -$811.5M |
| Accumulated other comprehensive income (loss) | -$5.1M-533.1% | $1.2M+439.7% | -$350K+39.0% | -$574K-1375.6% | $45K |
| Total stockholders' equity (deficit) | -$122.8M-516.2% | $29.5M-53.0% | $62.8M+419.7% | $12.1M-90.1% | $121.5M |
| Total liabilities and stockholders' equity (deficit) | $172.2M-45.4% | $315.3M+1.1% | $311.9M+14.5% | $272.4M-20.7% | $343.7M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.